Evidence map›Paper›PMID 42918929›Full record

ArticleJournal of cancer research and clinical oncology2026

Molecular tumor board in advanced sarcoma: treatment implementation and clinical outcomes in a real-world cohort.

Christoph Weinfurtner, Moritz Kaupp-Merkle, Ralf Marienfeld, Uwe Gerstenmaier, Jakob Niewöhner, Tobias Kolb, Axel Fürstberger, Sonja Dahlum, Paul Herzog, Ambros J Beer and 13 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Christoph WeinfurtnerDepartment of Internal Medicine III, University Hospital Ulm, Albert-Einstein-Allee 23, 89081, Ulm, Germany.
Moritz Kaupp-MerkleDepartment of Nuclear Medicine, University Hospital Ulm, Ulm, Germany.
Ralf MarienfeldInstitute of Pathology, University Ulm, Ulm, Germany.
Uwe GerstenmaierInstitute of Pathology, University Ulm, Ulm, Germany.
Jakob NiewöhnerInstitute of Pathology, University Ulm, Ulm, Germany.
Tobias KolbInstitute of Pathology, University Ulm, Ulm, Germany.
Axel FürstbergerInstitute of Pathology, University Ulm, Ulm, Germany.
Sonja DahlumInstitute of Human Genetics, University Hospital Ulm and Ulm University, Ulm, Germany.
Paul HerzogInstitute of Human Genetics, University Hospital Ulm and Ulm University, Ulm, Germany.
Ambros J BeerDepartment of Nuclear Medicine, University Hospital Ulm, Ulm, Germany.
Regine Mayer-SteinackerComprehensive Cancer Center Ulm, University Hospital Ulm and Ulm University, Ulm, Germany.
Meinrad BeerDepartment of Diagnostic and Interventional Radiology, University Hospital Ulm, Ulm, Germany.
Thomas F E BarthInstitute of Pathology, University Ulm, Ulm, Germany.
Thomas SeufferleinDepartment of Internal Medicine I, University Hospital Ulm, Ulm, Germany.
Nadine T GaisaInstitute of Pathology, University Ulm, Ulm, Germany.
Mathias WittauDepartment of General and Visceral Surgery, University Hospital Ulm, Ulm, Germany.
Stephan StilgenbauerComprehensive Cancer Center Ulm, University Hospital Ulm and Ulm University, Ulm, Germany.
Alexandra von BaerDepartment of Trauma Surgery, Hand Surgery, Plastic Surgery and Reconstructive Surgery, University Hospital Ulm, Ulm, Germany.
Markus SchultheißDepartment of Trauma Surgery, Hand Surgery, Plastic Surgery and Reconstructive Surgery, University Hospital Ulm, Ulm, Germany.
Reiner SiebertInstitute of Human Genetics, University Hospital Ulm and Ulm University, Ulm, Germany.
Wolfgang ThaissDepartment of Nuclear Medicine, University Hospital Ulm, Ulm, Germany.
Hartmut DöhnerDepartment of Internal Medicine III, University Hospital Ulm, Albert-Einstein-Allee 23, 89081, Ulm, Germany.
Verena I GaidzikDepartment of Internal Medicine III, University Hospital Ulm, Albert-Einstein-Allee 23, 89081, Ulm, Germany. verena.gaidzik@uniklinik-ulm.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAdvanced sarcomas remain therapeutically challenging. We evaluated treatment implementation and clinical outcomes after molecular tumor board recommendations.

methodsWe retrospectively analyzed 125 sarcoma patients discussed in our multidisciplinary Molecular and Familial Tumor Board between 2017 and 2023. Clinical benefit was assessed by treatment implementation and by the ratio of progression-free survival on molecularly guided therapy versus the preceding treatment line (PFS2/PFS1). Overall survival (OS) was measured from first board discussion.

resultsA total of 252 pathogenic or likely pathogenic variant records across 133 genes were identified. Molecular profiling enabled therapy recommendations in 71 of 125 patients (56.8%), with treatment implementation in 41 (32.8%). PFS2/PFS1 evaluation was feasible in 29 patients, and nine (31.0%) had a documented ratio > 1.3. Median PFS2 was 102 days (95% CI 63-233). Two of seven patients (28.6%) receiving poly(ADP-ribose) polymerase (PARP) inhibitor-containing regimens had ratios > 1.3. Median OS in 124 patients was 14.6 months (95% CI 11.7-18.5; global log-rank p = 0.220).

conclusionMolecular tumor board-guided therapy identified treatment options for selected sarcoma patients. Prolonged disease control in individual PARP-treated cases provides a positive signal that warrants prospective evaluation.

Indexed as

SarcomaAdolescentAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedMolecular Targeted TherapyPoly(ADP-ribose) Polymerase InhibitorsRetrospective StudiesTreatment OutcomeYoung AdultPoly(ADP-ribose) Polymerase InhibitorsHomologous recombination repairMolecular tumor boardPARP inhibitorPrecision oncologySarcomaTargeted therapy

Identifiers

PMID42918929

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.